MD-IONQ
14.3.2024 13:01:32 CET | Business Wire | Press release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, today announced early results from its work with Deutsches Elektronen-Synchrotron (DESY) – a German-based research center for fundamental science – to run combinatorial optimization problems on IonQ Aria. The results demonstrate quantum computing’s potential as a more effective solution than traditional classical computing when tackling equations with multiple variables in a dense environment, such as a bustling airport.
IonQ collaborated with researchers from DESY to explore how to better match inbound and outbound flights at airport gates. Specifically, IonQ and DESY were interested in reducing the time travelers spent going from arrival to departure gates and the time planes sat idle at gates before taking off again, while also increasing the number of planes serviced per day at a gate. The novel approach used ‘logarithmic-linear encoding’ to execute flight-gate optimization algorithms on IonQ Aria. In an illustrative example, the team showed how to best cycle nine flights through four gates (up to 36 variables in total) on IonQ Aria. IonQ expects to run future algorithms on IonQ Forte and IonQ Tempo, processing equations sufficient enough to cover the optimization needs of a local European airport.
“The results of our work with DESY are indicative of the real-world value quantum computers can deliver when addressing optimization problems that factor dozens of variable scenarios,” said Peter Chapman, CEO and President of IonQ. “Optimization problems are ubiquitous across all industries, including manufacturing, logistics, finance, pharma, and more. Quantum computing presents a huge opportunity for businesses to innovate across this problem space and remain at the forefront of innovation, tackling problems once deemed unsolvable.”
"We are pleased by the initial results we’re seeing in running quadratic assignment problems across IonQ’s quantum hardware and our collaboration with the IonQ team,” said Dr. Karl Jansen, the head of the Center for Quantum Technology and Applications (CQTA) at DESY. "The learnings gathered here can easily apply to other research and industries where the presence of multiple variables creates too complex of a problem for classical systems to handle."
A preprint explaining IonQ and DESY’s research is available here, with the final report expected to be published in the coming months, and a summary of these results is available on IonQ’s blog here.
These research results mark the latest effort by IonQ to support the development of quantum applications for the airline industry. In 2022, IonQ and Airbus partnered on a project to develop smarter algorithms based on quantum computers to achieve cost savings due to more efficient cargo loading and distribution. Additionally, Hyundai Motors and Thompson Machinery have partnered with IonQ to develop quantum applications for use cases like image recognition in autonomous vehicles and predictive maintenance for construction machinery.
To learn more about how you can get started on an IonQ system today, please contact us directly at: https://ionq.com/get-ready.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
About DESY
DESY is one of the world’s leading accelerator centers. Researchers use the large-scale facilities at DESY to explore the microcosm in all its variety – from the interactions of tiny elementary particles and the behavior of new types of nanomaterials to biomolecular processes that are essential to life. The accelerators and detectors that DESY develops and builds are unique research tools. The facilities generate the world’s most intense X-ray light, accelerate particles to record energies and open completely new windows onto the universe.
That makes DESY not only a magnet for more than 3000 guest researchers from over 40 countries every year, but also a coveted partner for national and international cooperations. Committed young researchers find an exciting interdisciplinary setting at DESY. The research center offers specialized training for a large number of professions. DESY cooperates with industry and business to promote new technologies that will benefit society and encourage innovations. This also benefits the metropolitan regions of the two DESY locations, Hamburg and Zeuthen near Berlin.
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “expect,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to: the company’s technology driving commercial advantage in the future; the applicability of IonQ’s quantum computing offerings to multiple use cases; access to IonQ’s quantum computers; the capabilities, scalability, and reliability of IonQ’s quantum computing offerings; the opportunity to test and optimize novel quantum-enhanced algorithms for computational challenges on IonQ’s quantum computers; the accuracy of quantum algorithms run on IonQ’s quantum computers; and the problems that can be solved by IonQ’s quantum computers. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates, including development of competing technologies; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, forecasts and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314520832/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
